Facebook: World Allergy Organization
Twitter: World Allergy Organization
LinkedIn: World Allergy Organization
Instagram: World Allergy Organization
Back to Top

Patient Education Programs in Allergy and Asthma

Patient education programs are helpful in ensuring correct use of medication and thus optimum control of symptoms. The World Health Organization/World Allergy Organization meeting report on Prevention of Allergy and Asthma lists the ideal content of patient education programs, based on review of many successful programs from around the world.

The information provided in this section may help you to identify areas for discussion with your doctor which will consolidate your understanding of your allergic disease and help you to manage your symptoms.


The following concepts and content should be included in physician-designed educational programs for patients:

Allergic asthma and allergic rhinitis

Guided self-management plans include:

  1. Good communication between patient and physician to improve patient compliance
  2. Understanding about the basic facts, causes and triggers of asthma/ allergic rhinitis
  3. Identifying and controlling factors that aggravate asthma/rhinitis symptoms and provoke exacerbations
  4. Following a written action plan to avoid or handle exacerbations
  5. Understanding the importance of proper drug use and correct use of spacers and inhalers, for long-term control
  6. Monitoring symptoms and peak flow values in persistent asthma and adjust medication accordingly

Atopic Eczema/Atopic Dermatitis

Educational programs in atopic eczema/atopic dermatitis should include:

  1. Information about nature, heredity, causes and triggers of atopic dermatitis/eczema
  2. Importance of identification and avoidance of individual provocation factors, skin care and treatment options, including complementary therapies
  3. Discussion of diagnosis and treatment of food allergies and adequate nutrition in childhood
  4. Behaviour-oriented psychological intervention programmes to interrupt the itching-scratching cycle.
  5. Training to improve stress-management and reduce the negative social effects of illness-specific problems

Severe Reactions, Allergic Anaphylaxis

Each patient should be provided with an individual management protocol to include the importance of:

  1. Carrying an epinephrine auto-injector and knowing how and when to use it;
  2. Always having a spare auto-injector available
  3. Ensuring auto-injectors are replaced as soon as the use-by date has expired
  4. Carrying an emergency pager or mobile telephone
  5. Carrying/wearing Medic-Alert information
  6. Avoiding stinging insects, learning how not to attract them
  7. Avoiding allergenic ingredients in ready-made food

    In school environment:
    Education of parents, teachers, fellow students, and school administrators is necessary to provide a safe environment for children at risk for anaphylaxis to foods or insect stings.

  8. Creating a no-food area of the school playground
  9. Identifying a supervisor to carry a telephone for emergencies

    In occupational environment:
    Health and Safety measures should be introduced to prevent exposure of affected workers to airborne or contact allergens


© World Health Organization 2003

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to Publications, at the above address (fax: +41 22 791 4806; email:

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.


Printed by the WHO Document Production Services, Geneva, Switzerland